Date: 2018-10-16
Type of information: Nomination
Compound: member of the board of directors
Company: Ziopharm Oncology (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 16, 2018, Ziopharm Oncology announced changes to its Board of Directors and management team. Ziopharm’s Chief Executive Officer Laurence Cooper is appointed to the Board of Directors effective immediately, and Francois Lebel is stepping down from his position as Chief Medical Officer (CMO) and Executive Vice President of Research & Development, effective Oct. 26.
- Ziopharm recently announced it has full developmental control over its technologies and is now evolving its organizational structure. A recruitment process is underway during this transition period aimed at building upon existing expertise to meet the needs of patients and shareholders.
Financial terms:
Latest news:
Is general: Yes
